I
N THE search for new and more rewarding approaches to the diagnosis and treatment of nlalignant gliomas, a study of the antigenic potential of this rather unique type of tumor was initiated. The glioblastoma multiforme is characterized by its infiltrative and locally invasive behavior, the rarity of true metastasis, the proliferation of supportive vascular stroma, and a tendency of the tumor to recur despite surgical resection, irradiation therapy, and chemotherapy. Previous experiments with the use of regional carotid chemotherapeutic perfusion and infusion have demonstrated the lack of specificity of anti-cancer agents and their toxicity to normal brain tissue. 10,1s,19
Delivery of radioactivity or an anti-cancer agent to a glioma by use of specific antibody carriers would offer another approach to the diagnosis and treatment of these tumors. Specific localization of radioiodine emitting energetic gamma ray would sharpen the tumor profile obtained by external scanning procedures. 12 Specific localization of radioiodine emitting beta rays might be expected to concentrate therapeutic amounts of radioactivity within the tumor with nfinimal radiation damage to the adjacent normal brain tissue?
These considerations led to an investigation of the antigenic potential of human gliomas, based upon an experimental model system with rat hepatoma, s Thus, the in Received for publication October le, 1964. * This paper in part received the 1965 award by the American Academy of Neurological Surgery, and in that form was presented at the annual meeting of the Academy, Cincinnati, Ohio, October [14] [15] [16] 1965 . vitro and clinical studies outlined in this paper and the related studies described elsewhere 3,4,5,9 were designed first, to determine the feasibility of localizing radioantibody in human gliomas and, second, to establish a baseline for assays of localized antibody from which to determine the purity, concentration and localizing properties of subsequent radioantibody preparations.
Production of Antibody
At the time of primary craniotomy, each specimen was divided grossly into glioma, invasive zone, and normal adjacent brain. The three portions were homogenized in borate buffer and separated by low-speed centrifugation into collagen-rich stromal sediment (which also contained the majority of the parenchymal elements) and supernatant fluid. The sediments were lyophilized and stored at -~0~ until needed. The stromal sediment was used for the imnmnization of rabbits, each receiving an injection of sediment (10 mg.) contained in complete Freund's adjuvant in the foot pads as an initiating dose, followed by a booster injection intraperitoneally ~ weeks later. Each rabbit was exsanguinated 1 month after the initial sediment injection. The gamma-globulin fraction of the serum was precipitated three times in 3M ammonimn sulphate, dissolved in and dialyzed against saline, lyophilized, and stored at -~0~ until needed. A more satisfactory technique for differential separation of stroma (dense), parenchyma (light), and supernatant fluid has recently been found. A test a3 for the presence of collagen (hydroxyproline) in these three fractions in the tumor portion from 1 patient (No. ~8) demonstrated that almost all of the collagen could be separated into the stromal $63 (Table 1) . This separation technique has been used recently to obtain stromal and parenchymal sediments for imnmnizing rabbits aganist each. The presence of antibody during the purification procedure and within the biopsied tissue after infusion was assayed by a radioactive label (1125 or I131). The IC1 method 14 for high specific labeling of protein with radioiodine was used. The unbound iodine was removed by dialysis and/or by passing the globulin solution through a column of DEAE-A-50 sephadex. In all the clinical studies done thus far (except patient No. 36), it has been necessary to label the globulin fraction prior to in vitro purification. Work is now under way to develop a technique for labeling the purified antibody in order to allow delivery, during infusion, of a higher concentration of radioactivity attached to the purified antibody2
In Vitro Purification Methods developed earlier 2 were used here with slight modification. 3 In vitro purification can be accomplished by absorbing the globulin fraction (~ rag.) onto the original antigenic sediment (4 mg.) and then retrieving that portion of the globulin which had attached itself to the homologous sediment, (by elution at 60~ in pH 8 buffered saline), alternatively the globulin fraction can be absorbed onto normal brain or other tissue sediments to remove those portions of the globulin fraction which cross-react with other tissues and are not specific for the glioma sediment. In some cases, both in vitro purification procedures (elution and absorb more specifically onto the homologous sediment. To illustrate, radioantibody prepared against the glioma of patient No. 9, after absorption on and elution from the homologous tumor sediment, was divided in half. One half (eluate A) was tested without further purification; the other half was absorbed with normal brain sediment and centrifuged, the supernatant fluid being used as eluate B. The ~ eluates were diluted and tested for re-absorption onto various tumor and brain sediments (Table ~2 ). Eluate A was found to contain some antibodies that would cross-react with normal brain not only of hunmn but also of rat and (tog. A single absorption with normal human brain sediment (eluate B) reduced the cross-reaction with dog and rat brain to a level expected only for non-specific absorption and reduced the cross-reaction with human brain by half. It was found later that s snore brain absorptions would be necessary to reduce this crossreaction to a control level. Absorption with human brain also reduced the cross-reaction with tumor sediments from other human gliomas but left considerable antibody that would react with the homologous tumor (No. 9). Such absorptions of antibody onto heterologous sediments and elution from the homologous glioma sediment should permit in vitro purification of a relatively specific antiglioma-stroma or anti-parenchyma antibody for each patient. 
